期刊文献+

利福昔明合成工艺的研究 被引量:2

Research on synthesis of rifaximin
下载PDF
导出
摘要 以利福霉素S和2-氨基-4-甲基吡啶为原料,二氯甲烷为溶剂,碘为催化剂,亚硫酸钠为还原剂,合成一种新药利福昔明。结果表明,优化工艺条件为:利福霉素S与催化剂碘的摩尔比为3∶1,2-氨基-4-甲基吡啶与利福霉素S的摩尔比为2.5∶1,反应温度为30℃,反应时间为24 h。在该优化条件下,产品的产率达85.2%。 A new-type drug, rifaximin was synthesized with rifamycin S and 2-amino-4-methyl-pyridine in the presence of iodine as catalyst and sodium sulfite as reducing agent, the reaction is carried out in di- chloromethane. The result showed that the optimum reaction conditions were determined as follows:the molar ratio of rifamycin S to iodine of 3: 1, the molar ratio of 2-amino-4-methyl-pyridine to rifamycin S of 2.5: 1, reaction temperature of 30 ℃, reaction time of 24 h. Under the optimum condition, the yield of the product reached 85.2%.
出处 《应用化工》 CAS CSCD 2013年第10期1801-1803,共3页 Applied Chemical Industry
基金 湖南省自然科学基金项目(13JJ3099) 湖南省科技计划项目(2012SK3134) 中南大学中央高校基本科研业务费专项资金项目(2012zzts053) 中南大学自由探索创新项目(2282013bks019)
关键词 利福昔明 合成 利福霉素S 2-氨基-4-甲基吡啶 rifaximin synthesis rifamycin S 2-amino-4-methyl-pyridine
  • 相关文献

参考文献8

  • 1Feret Brett, Barner Benjamin. Rifaximin : a nonabsorbable, broad-spectrum antibiotic for reduction in the risk for re- currence of overt hepatic encephalopathy [ J ]. Formulary, 2010,7(45) :210-216.
  • 2吴书妹,周莹群,郭传勇.利福昔明在消化道疾病中的应用进展[J].世界临床药学,2012,33(12):752-754.
  • 3吴书妹,郭传勇.利福昔明治疗肝性脑病的研究进展[J].实用肝脏病杂志,2012,15(6):602-604. 被引量:1
  • 4任淑萍,陈瑞玲.利福昔明的临床应用[J].临床药物治疗杂志,2005,3(6):38-40. 被引量:9
  • 5王佩,李玉珍.利福昔明的药理作用和临床应用[J].药物不良反应杂志,2005,7(5):382-385. 被引量:17
  • 6ALFA Farmaceutici S P A. Process for the synthesis of pyfido-imidazo rifamyeins : US, 4557866A [ P ]. 1985-04- 26.
  • 7ALFA Farmaceutici S P A. Process for the synthesis of imidazo rifamycins : CA, 1215976A1 [ P]. 1986-12-30.
  • 8ALFA Farmaceutici S P A. Process for the synthesis of pyrido-imidazo-rifamycins : CA, 1218650A1 [ P ]. 1985-09- 25.

二级参考文献57

  • 1王佩,李玉珍.利福昔明的药理作用和临床应用[J].药物不良反应杂志,2005,7(5):382-385. 被引量:17
  • 2任淑萍,陈瑞玲.利福昔明的临床应用[J].临床药物治疗杂志,2005,3(6):38-40. 被引量:9
  • 3崔东来,陈卫,姚希贤.利福昔明在消化疾病中的临床应用进展[J].世界华人消化杂志,2007,15(13):1457-1462. 被引量:3
  • 4[2]Dupont HL,Jiang ZD,Ericsson CD,et al. Rifacimin versus ciprofloxacin for the treatment for travlersdiarrhea: a randomized,double - blind clinical trail. Clin Infect Dis, 2001,33:1807~1815
  • 5[3]Di Stefano M, Strocchi A, Malsevisi S, et al. Non - absorbable antibiotics for managing intestinal gas production and gas - raelated symptoms. Aliment Pharmacol Ther, 2000,14:1001 ~ 1008
  • 6[4]Di Stefano M, Maiservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short - term treatment of small intestinal bacterical overgrowth. Aliment Pharmacol Ther, 2001, 14:551~556
  • 7[5]Infante RM, Ericsson CD, Jiang ZD, et al. Eteroaggragative scherichia coli diarrhea intraverlers:response to rifaximin therapy. Clin Gastroenterol Hepatol,2004,2(2): 135 ~ 138
  • 8李晓娟,于岩岩,侯风琴,等.利福昔明治疗急性肠炎251例临床观察[J].中国临床药理学杂志,2002,4(18):263-267.
  • 9杨卫红,周丽雅,林三仁,等.利福昔明治疗急性肠道感染的多中心随机对照临床试验研究[J].中国实用内科杂志,2003,12(23):753-754.
  • 10[8]Williams R, James OF, Warnes TW, et al. Evaluation of the efficacy and safty of rifaximin the treatment of hepaticencephalopathy: a double - blind, randomized, dose - finding multi - centre study. Eur J Gastroenterol Hepatol,2000,12:203 ~ 208

共引文献21

同被引文献33

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部